A Clinical Study of Enlicitide (MK-0616) in Adults With Hyperlipidemia in India (MK-0616-038)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Enlicitide Decanoate in Adults With Hyperlipidemia in India
- Hyperlipidemia
- Hypercholesterolemia
At a glance
- Phase
- Phase 3
- Study type
- Interventional
- Sponsor
- Merck Sharp & Dohme LLC
- Enrolment target
- 150
- Started
- 15 October 2026
- Main results due (estimated)
- 26 November 2027
- Study ends (estimated)
- 26 November 2027
- Allocation
- Randomized
- Design
- Parallel
- Purpose
- Treatment
- Masking
- Triple (participant, investigator, outcomes assessor)
- Sites
- 2 · 2 in India
- First posted
- 16 September 2026
- Registry updated
- 2 November 2026
Can you take part?
- Aged 18 years and over.
- Open to any sex.
- You need the condition being studied. Healthy volunteers are not accepted.
Age groups: adult, older adult.
These are the headline rules. Every study has a longer list, and whether you are eligible is decided by the research team at the site, never by this page.
Read the full eligibility criteria
Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * History of a major atherosclerotic cardiovascular disease (ASCVD) event or if no history of a major ASCVD event, has one or more of the following: possible or definite diagnosis of heterozygous familial hypercholesterolemia (HeFH), diabetes mellitus, stable angina pectoris, transient ischemic attack or symptomatic peripheral arterial disease * Has a low-density lipoprotein cholesterol (LDL-C) ≥55 mg/dL or ≥70 mg/dL depending on medical history * Is treated with a moderate- or high-intensity statin OR is treated with low-intensity statin with documentation of intolerance to a moderate or high-intensity statin OR is not receiving statins with documentation of statin intolerance * If on any lipid-lowering therapies (LLTs), should be on a stable dose with no planned medication change Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * Had a heart failure hospitalization within 3 months before Screening * Has unstable angina, a myocardial infarction, coronary artery bypass graft, percutaneous transluminal coronary angioplasty, transient ischemic attack, or stroke within 3 months before Screening * Is undergoing or previously underwent an LDL-C apheresis program within 3 months before first study visit or plans to initiate an LDL-C apheresis program * Was previously treated/is being treated with certain other cholesterol lowering medications, including protein convertase subtilisin/kexin type 9 (PCSK9) inhibitors * Has a history of nephrotic syndrome * Has poorly controlled diabetes mellitus * Has hyperthyroidism or inadequately controlled hypothyroidism * Is actively receiving chemotherapy for malignancy or has a history of malignancy ≤3 years before Screening
What this study is about
In the sponsor’s own words, from the registry.
Researchers are looking for new ways to treat high cholesterol. Cholesterol is a type of fat in the blood.
Enlicitide (also known as enlicitide decanoate or MK-0616), the study medicine, is in a class of medicines designed to lower low-density lipoprotein cholesterol (LDL-C). LDL-C is sometimes called "bad cholesterol."
The goal of this study is to learn if enlicitide works better than placebo to lower the amount of LDL-C in a person's blood. Researchers also want to learn about the safety of enlicitide and if people tolerate it.
What participants receive
- Experimental
Enlicitide Decanoate
Participants will receive 20 mg enlicitide decanoate orally once daily (qd) for up to 24 weeks.
Drug: Enlicitide Decanoate
- Other
Placebo
Participants will receive placebo orally qd for up to 24 weeks.
Other: Placebo
Interventions
Enlicitide DecanoateDrug
Also known as MK-0616, enlicitide
Oral administration
PlaceboOther
Oral administration
What the study measures
Primary outcomes
Mean Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 24
Blood samples will be collected at baseline and at Week 24 to assess mean percent change in LDL-C.
Time frame: Baseline and Week 24
Number of Participants with One or More Adverse Events (AEs)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: Up to approximately 32 Weeks
Number of Participants who Discontinue Study Drug Due to One or More AEs
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: Up to approximately 24 Weeks
Secondary outcomes
Mean Percent Change From Baseline in Non High-Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24
Blood samples will be collected at baseline and at Week 24 to assess mean percent change in non-HDL-C.
Time frame: Baseline and Week 24
Mean Percent Change From Baseline in Apolipoprotein B (ApoB) at Week 24
Blood samples will be collected at baseline and at Week 24 to assess mean percent change in ApoB.
Time frame: Baseline and Week 24
Percent Change From Baseline in Lipoprotein (a) (Lp(a)) at Week 24
Blood samples will be collected at baseline and at Week 24 to assess percent change in Lp(a)
Time frame: Baseline and Week 24
Percentage of Participants With LDL-C <70 mg/dL and ≥50% Reduction From Baseline at Week 24
Blood samples will be collected at baseline and at Week 24 to assess the percentage of participants who have LDL-C \<70 mg/dL and ≥50% reduction from baseline.
Time frame: Baseline and Week 24
Percentage of Participants With LDL-C <55 mg/dL and ≥50% Reduction From Baseline at Week 24
Blood samples will be collected at baseline and at Week 24 to assess the percentage of participants who have LDL-C \<55 mg/dL and ≥50% reduction from baseline.
Time frame: Baseline and Week 24
Who is running it
- Lead sponsor
- Merck Sharp & Dohme LLC
- Sponsor type
- Industry
- Responsible party
- The sponsor
- Organisation
- Merck Sharp & Dohme LLC
- Data monitoring committee
- Yes
- US FDA-regulated drug
- Yes
- US FDA-regulated device
- No
- Sponsor's study ID
- 0616-038
Medical Director
Study director
Merck Sharp & Dohme LLC
Study sites(2)
KLES Prabhakar Kore Hospital & Medical Research Centre [M] ( Site 1004)
Belagavi, Karnataka, India
Recruiting
- Study Coordinator8312473777
Sir Ganga Ram Hospital ( Site 1001)
New Delhi, National Capital Territory of Delhi, India
Recruiting
- Study Coordinator+911142254000
Showing 2 of 2 sites. 2 recruiting, 0 not recruiting and 0 cancelled; 2 in India. Not recruiting covers sites not yet open, finished enrolling, completed or paused; cancelled covers sites withdrawn before opening or stopped for good.
References and data sharing
- Participant data shared
- Yes
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Source: ClinicalTrials.gov record NCT07821944, status verified October 2026. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Interested in this study?
Tell us how to reach you and we will connect you with the study team. Or refer someone you care for, with their permission.